Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 257Neoplasms 225Carcinoma, Non-Small-Cell Lung 206Colorectal Neoplasms 148Prostatic Neoplasms 142Lung Neoplasms 116Neoplasm Metastasis 106Ovarian Neoplasms 103Multiple Myeloma 98Pancreatic Neoplasms 89Leukemia, Myeloid, Acute 79Squamous Cell Carcinoma of Head and Neck 75Endometrial Neoplasms 65Melanoma 64Stomach Neoplasms 60Recurrence 59Glioblastoma 57Brain Neoplasms 56Urinary Bladder Neoplasms 51Carcinoma, Hepatocellular 51Triple Negative Breast Neoplasms 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Lymphoma 48Head and Neck Neoplasms 47Carcinoma, Renal Cell 46Hematologic Neoplasms 44Esophageal Neoplasms 43Colonic Neoplasms 43Uterine Cervical Neoplasms 42Glioma 42

Interventions

BCG Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Carcinoma in Situ × 30 days × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05951179 2026-05-18

ADVANCED-2

Protara Therapeutics

Phase 2 Recruiting
131 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡